Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.18 (8.955%)
Market Cap: £44.34m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Business Update

10 Jun 2025 07:00

RNS Number : 0858M
Quadrise PLC
10 June 2025
 

Certain of the information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

10 June 2025

 

Quadrise plc

("Quadrise", "QED" or the "Company")

 

Business Update

 

 

Quadrise plc (AIM: QED), the technology company focused on the decarbonisation of shipping and heavy industry through deployment of low emission fuels and biofuels, is pleased to provide an update covering progress on its key projects.

Marine

The expected bilateral agreements between MSC and Cargill, and Cargill and Quadrise, to initiate the commercial-scale marine trials are now in near final form and are expected to be concluded soon. Following signature, the trial equipment will be installed and commissioned at the MAC2 site in Antwerp, ahead of the commercial-scale marine trials commencing in Q3 2025.

Quadrise continues to make strong progress in building strategic partnerships with additional potential customers, aimed at accelerating the commercialisation of bioMSAR™ and MSAR®. The Company intends to utilise its facilities at MAC2 to service these opportunities, as well as establishing similar supply points in other major marine bunker hubs.

Morocco

The planned commercial trial with OCP to establish MSAR® supply in the Mediterranean continues to progress. Following relocation to an alternative production line and associated kiln by OCP, the Company has deployed all necessary trial equipment to site. To commence the 30-day paid trial, Quadrise is awaiting approval from the original equipment manufacturer of the kiln and burner system ("OEM"), which is expected to be received in Q3 2025, with the trial commencing immediately thereafter.

In parallel, Quadrise and the OEM are exploring potential collaboration opportunities with other industrial clients.

Americas

In Panama, excellent progress continues to be made for our trial with Sparkle Power SA. Trial equipment and chemicals have been shipped to site, with the trial now expected to start during Q3 2025. This will be the first test for Quadrise on a MAN 4-stroke diesel engine, expanding our application experience with this significant engine manufacturer. A successful trial would be expected by the Company to lead to a Fuel Supply Agreement with a supplier and to facilitate discussions with other regional power producers.

US Low Carbon Fuels

Quadrise is now awaiting delivery of a new batch of oil samples from Valkor's Primary Project Site ('PPS') at Asphalt Ridge, Utah, USA as the previous samples tested were deemed unrepresentative of Valkor's expected final oil output. Once testing of these samples has been positively concluded, marketing of MSAR® and bioMSARTM fuels in the USA can then commence.

Quadrise now expects to deliver a smaller 600bpd Multifuel Manufacturing Unit ("MMU") to the PPS in Q3 2025, with the US$75k per quarter technology transfer fee payable by Valkor to Quadrise commencing from the date of delivery.

bioMSAR™ and bioMSAR™ Zero development

Quadrise continues to advance several joint development and commercial discussions and testing with potential partners and customers to deliver cleaner fuels at a lower cost than alternatives.

 

Andy Morrison, Chair of Quadrise, commented:

"Quadrise has continued to make progress throughout 2025 to date. Whilst some developments have taken longer than originally anticipated, we are more convinced than ever in the strength of our technology, the scale of the opportunity, and our ability to successfully deliver on our strategy.

"We enter the next quarter with real momentum and expect to achieve several important operational milestones which will bring us significantly closer to commercial deployment and long-term value creation for our shareholders."

 

For further information please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Technology Officer

 

 

Nominated Adviser

Cavendish Capital Markets Limited

 

 

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

 

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Harry Davies-Ball (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Tavistock Communications (Financial PR & IR)

Simon Hudson

Nick Elwes

Ruairi Millar

 

+44 (0) 20 7920 3150

 

 BLUE Communications Limited (Marine & Trade PR)

 Rhys Thomas

 Sam Deacon

 

 

 

+44 (0)7595 227750

+44 (0)7527 558846

 

 

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X: @QuadrisePlc

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGZGGVNLVGKZM
Date   Source Headline
15th Apr 20267:00 amRNSDirectorate change
23rd Mar 20267:00 amRNSInterim Results & Notice of Investor Presentation
19th Mar 20267:00 amRNSAppointment of Non-Executive Director
3rd Feb 20267:00 amRNS-RPublication of 2025 Sustainability Report
12th Jan 20267:00 amRNSExtension of Exclusive Agreement with Nouryon
9th Jan 20267:00 amRNSDirector/PDMR Shareholding and Directorate Change
4th Dec 202512:17 pmRNSDirector/PDMR Shareholding
28th Nov 20252:55 pmRNSResult of AGM
28th Nov 20257:00 amRNSAGM Statement
7th Nov 20253:01 pmRNSDirector/PDMR Shareholding
6th Nov 20251:46 pmRNSDirector/PDMR Shareholding
28th Oct 20255:23 pmRNSPosting of Annual Report and Notice of AGM
27th Oct 20257:00 amRNSIssue of Options and Director Dealing
13th Oct 20257:00 amRNSIssue of Share Options and Director/PDMR Dealing
29th Sep 20257:00 amRNSFinal Results and Notice of AGM
26th Sep 20257:00 amRNSValkor update
17th Sep 20257:00 amRNSSuccessful Sparkle Power Programme Testing
15th Sep 20257:00 amRNSCEO Appointment
18th Aug 20257:00 amRNSBusiness Update
25th Jul 20257:00 amRNSDirector / PDMR Shareholding
14th Jul 20258:00 amRNSDirector/PDMR Shareholding
4th Jul 202511:50 amRNSExercise of Options and Total Voting Rights
17th Jun 20257:00 amRNSJoint Development Agreement with Alder Energy LLC
10th Jun 20257:00 amRNSBusiness Update
23rd May 20257:00 amRNSExercise of Warrants
1st May 20257:01 amRNSTotal Voting Rights
1st May 20257:00 amRNSManagement Update
3rd Apr 20257:00 amRNSExercise of Share Options
1st Apr 20257:00 amRNSMAC2 Services Agreement
26th Mar 202512:46 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSLicella Joint Development Agreement
24th Mar 20257:00 amRNSInterim Results and Investor Presentation
13th Mar 20257:00 amRNS-RAppointment of Head of Marine
31st Jan 20257:00 amRNSResult of Retail Offer
30th Jan 20252:36 pmRNSIncrease of Retail Offer
28th Jan 20257:00 amRNSAppointment of Director
24th Jan 202510:04 amRNSRetail Offer - Notice of IMC Presentation
24th Jan 20257:05 amRNSRetail Offer
24th Jan 20257:00 amRNSResult of Placing and Subscription
23rd Jan 20254:51 pmRNSProposed Placing, Subscription and Retail Offer
15th Jan 20257:00 amRNSValkor License Revenues
16th Dec 20247:00 amRNSMaterial Transfer Agreement with Sparkle Power SA
5th Dec 20247:00 amRNS-RbioMSAR™ Development Update
26th Nov 20247:00 amRNSProject Agreement with MSC and Cargill
25th Nov 20247:00 amRNSCollaboration Agreement with Auramarine
22nd Nov 20244:57 pmRNSResult of AGM
22nd Nov 20247:00 amRNSAGM Statement
25th Oct 20244:05 pmRNSPosting of Annual Report & Notice of AGM
30th Sep 20247:00 amRNSFinal Results and Notice of AGM
2nd Aug 20247:00 amRNSIssue of Share Options and Director/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.